Breast Cancer Clinical Trials 2022

Browse 221 Breast Cancer Medical Studies Across 668 Cities
43 Phase 3 Trial · 4463 Breast Cancer Clinics

Display Results

All

Most EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Breast Cancer Clinical Trials 2022

Reviewed by Michael Gill, B. Sc.

Image of Tranquil Clinical Research in Webster, United States.

Phase-Based Progress Estimates

Treatment Cohort Arm 1 Modified Regimenfor Estrogen Receptors

This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal (still having periods) women with ER+/HER2- breast cancer. This study includes a pharmacokinetic part (PK, how the drug works in your body) and a treatment part. The primary purpose of the study is to see how (Z)-endoxifen works on tumor cell growth by taking a biopsy after 4 weeks of treatment to measure Ki-67. Ki-67 is a cancer marker that indicates how well the treatments work to slow cancer cell growth. Overall, this study will help determine if (Z)-endoxifen can effectively treat premenopausal women with ER+/HER2- breast cancer without the need for monthly injections of goserelin which is a medication given to block the ovaries from making estrogen (also called ovarian suppression). Studies have shown harmful long-term effects of ovarian suppression in premenopausal women. The PK part of the study will be enrolled first, enrolling about 6 study participants who will all receive oral once daily (Z)-endoxifen treatment. This part of the study will help select the dose of (Z)-endoxifen to use in the treatment part by measuring the levels of (Z)-endoxifen in the blood stream and determine how long it takes for the body to remove it. About 160 study participants will be enrolled in the treatment part. The treatment part will help to determine how oral once daily (Z)-endoxifen, when taken by itself, compares to oral once daily exemestane (a medication that decreases the amount of estrogen in the body, also known as an aromatase inhibitor) and monthly injections of goserelin. Exemestane and goserelin taken together is a standard treatment regimen for premenopausal patients with ER+/HER2- breast cancer. Study participants are randomly assigned to treatment with an equal (50/50) chance to be assigned to (Z)-endoxifen or standard treatment. Study participation is up to 24 weeks of treatment followed by surgery.

Tranquil Clinical ResearchMatthew P Goetz, MDAtossa Therapeutics, Inc.

Image of Dana Farber Cancer Institute in Boston, United States.

Phase-Based Progress Estimates

10e7 PFU Dose 3 Injectionsfor Breast Cancer

Waitlist Available

The goal of this phase 1 open label clinical trial is to evaluate the safety and preliminary efficacy of CodaLytic, an intratumorally-administered oncolytic virus, in patients with metastatic or otherwise inoperable breast cancer. The main questions it aims to answer are: How safe is CodaLytic when administered in escalating dosing groups into targeted lesions? What is the impact of CodaLytic on lesion response and disease progression? Eligible participants will be enrolled into four (4) escalating dose groups and treated with Codalytic through injection into a selected lesion(s) over twelve (12) weeks and then followed for up to one (1) year after the first dose. A safety committee will review the safety profile of each dosing group before the next dose-escalation. Study procedures will include physical examinations, injection site assessments, biopsies, imaging, and collection of blood/urine to assess safety, the body's immune response, and efficacy.

Waitlist Available

Dana Farber Cancer Institute (+1 Sites)Codagenix, Inc

Image of St. Bernards Medical Center in Jonesboro, United States.

Phase-Based Progress Estimates

Imlunestrantfor Breast Cancer

This trial is testing whether immunestrant works better than standard hormone therapy for people with early breast cancer who are estrogen receptor positive and human epidermal receptor 2 negative.

St. Bernards Medical Center (+28 Sites)Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company

Image of St-Sacrement Hospital in Quebec City, Canada.

Phase-Based Progress Estimates

Angiomammographyfor Breast Cancer

This trial is looking at whether a less expensive and more readily available diagnostic modality, namely CESM, is as effective as MRI in predicting the response of a malignant breast tumor to neoadjuvant chemotherapy and the chances of achieving a pCR.

St-Sacrement Hospital

Image of Gabrail Cancer Center in Canton, United States.

Phase-Based Progress Estimates

Elacestrantfor Central Nervous System Diseases

This trial is testing a new combination drug treatment for breast cancer that has spread to the brain. It is open to men and women with this type of breast cancer.

Gabrail Cancer Center

Image of City of Hope (City of Hope National Medical Center, City of Hope Medical Center) in Duarte, United States.

Phase-Based Progress Estimates

PF-07260437for Ovary Cancer

This trial is testing a new cancer treatment targeting B7-H4 expressing tumors. The safety and effectiveness of the treatment will be evaluated in adults with advanced breast, ovarian, or endometrial cancer.

City of Hope (City of Hope National Medical Center, City of Hope Medical Center) (+13 Sites)Pfizer CT.gov Call CenterPfizer

Image of Ironwood Cancer & Research Centers in Chandler, United States.

Phase-Based Progress Estimates

LY3484356for Breast Cancer

FDA Approved Drug

This trial is testing a new drug to see if it's more effective than standard hormone therapy for treating breast cancer.

FDA Approved Drug

Ironwood Cancer & Research Centers (+40 Sites)Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company

Image of University of Alabama at Birmingham in Birmingham, United States.

Phase-Based Progress Estimates

Abemaciclibfor Breast Cancer

Waitlist Available

FDA Approved Drug

This trial is testing abemaciclib as a treatment for early breast cancer in people who are also taking hormone therapy. It will last up to 10 years.

Waitlist Available

FDA Approved Drug

University of Alabama at Birmingham (+99 Sites)Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company

Image of GSK Investigational Site in Atlanta, United States.

Phase-Based Progress Estimates

Niraparibfor Breast Cancer

Waitlist Available

FDA Approved Drug

This trial is for people who are already taking niraparib in other trials and want to keep taking it. The goal is to learn more about the long-term safety of the drug.

Waitlist Available

FDA Approved Drug

GSK Investigational Site (+13 Sites)GSK Clinical TrialsGlaxoSmithKline

Image of Moores Cancer Center in La Jolla, United States.

Phase-Based Progress Estimates

CX-2009for Breast Cancer

Waitlist Available

This trial will study CX-2009 as a possible treatment for metastatic breast cancer.

Waitlist Available

Moores Cancer Center (+34 Sites)Virginia E. Paton, Pharm DCytomX Therapeutics

Image of Smilow Cancer Hospital at Yale - New Haven in New Haven, United States.

Phase-Based Progress Estimates

PF-07220060for Breast Cancer

FDA Approved Drug

This trial is testing a new drug, PF-07220060, to see if it is safe and effective when used alone or in combination with other drugs. The trial will be conducted in four parts, with escalating doses in the first part to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). The second part of the trial will test the drug in combination with two different endocrine therapies (letrozole and fulvestrant). The third part of the trial will assess the food effect of the RP2D dose from Part 1A. The fourth part of the trial will be an expansion for combination

FDA Approved Drug

Smilow Cancer Hospital at Yale - New Haven (+8 Sites)Pfizer CT.gov Call CenterPfizer

Image of Albert Einstein Medical Center Montgomery in East Norriton, United States.

Phase-Based Progress Estimates

Parallel Placementfor Surgical Wound

This trial is testing whether in-line or perpendicular placement of Steri-Strips on breast surgery incisions affects healing. Patients' age, comorbid conditions, type of breast surgery, and treatment with pre-operative or post-operative chemotherapy or radiation therapy will be reviewed to ensure similar study groups. Steri-Strips will be allowed to fall off naturally and pictures will be taken of the incisional area at 30-day and 90-day follow-ups. A blinded, independent surgeon will grade each incision according to the modified Hollander Cosmesis Scale. Statistical analysis will be performed to determine significance of the

Albert Einstein Medical Center Montgomery (+1 Sites)Candace L Ward, MD, MPH

Image of Florida Cancer Specialists South - SCRI - PPDS in Sarasota, United States.

Phase-Based Progress Estimates

Palbociclib (75, 100, 125 Milligram [mg])for Receptors, Estrogen

Waitlist Available

FDA Approved Drug

This trial is testing a combination of two drugs to treat estrogen receptor-positive breast cancer. The goal is to find the maximum tolerated dose and/or the recommended Phase 2 dose of the combination.

Waitlist Available

FDA Approved Drug

Florida Cancer Specialists South - SCRI - PPDS (+4 Sites)H3 Biomedicine Inc.

Image of Baylor College of Medicine in Houston, United States.

Phase-Based Progress Estimates

Sitravatinibfor Breast Cancer

This trial is testing a new drug, sitravatinib, to see if it can help people with metastatic breast cancer. Everyone in the study will take sitravatinib daily to see if it can help their cancer.

Baylor College of MedicineMirati Therapeutics Inc.

Image of Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, United States.

Phase-Based Progress Estimates

Contrast Enhanced Digital Mammographyfor Breast Cancer

Waitlist Available

This trial is testing how well contrast enhanced mammography can diagnose patients with suspicious breast findings. The hope is that it will help to reclassify findings that would otherwise require a biopsy.

Waitlist Available

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityLydia Liao

Image of 10 sites incl TX, WA, VA, and NV in Dallas, United States.

Phase-Based Progress Estimates

Trastuzumabfor Breast Cancer

FDA Approved Drug

This trial is testing ibrutinib given with trastuzumab to see if it is safe and what the highest dose that can be given is. It is for people with HER2-positive metastatic breast cancer that has gotten worse after other treatments.

FDA Approved Drug

10 sites incl TX, WA, VA, and NVJoyce O'Shaughnessy, MDAbbVie

Image of Yale University in New Haven, United States.

Phase-Based Progress Estimates

Dietary/Physical Activity Interventionfor Breast Cancer

Waitlist Available

This trial will compare the effects of a diet and exercise intervention against usual care on breast cancer patients undergoing chemotherapy.

Waitlist Available

Yale University (+1 Sites)Tara Sanft, M.D.

Image of Mount Sinai Beth Israel Comprehensive Cancer Center West in New York, United States.

Phase-Based Progress Estimates

Palbociclibfor Breast Diseases

Waitlist Available

FDA Approved Drug

This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.

Waitlist Available

FDA Approved Drug

Mount Sinai Beth Israel Comprehensive Cancer Center West (+4 Sites)Amy Tiersten, MD

Image of Cancer Center of Southern California in Santa Monica, United States.

Phase-Based Progress Estimates

Xentuzumabfor Breast Cancer

Waitlist Available

FDA Approved Drug

This trial is testing the combination of two drugs, xentuzumab and abemaciclib, to see if they are safe and effective at shrinking tumors in patients with lung and breast cancer.

Waitlist Available

FDA Approved Drug

Cancer Center of Southern California (+3 Sites)Boehringer IngelheimBoehringer Ingelheim

Image of Highlands Oncology Group in Fayetteville, United States.

Phase-Based Progress Estimates

P10s-PADRE With MONTANIDE™ ISA 51 VG + Doxorubicin + Cyclophosphamide + Paclitaxelfor Breast Cancer

Waitlist Available

FDA Approved Drug

This trial is testing a new cancer vaccine in people with TNBC. The vaccine will be given with standard neoadjuvant chemotherapy (chemo given before surgery). The trial will compare how well the vaccine works when added to standard neoadjuvant chemo to standard neoadjuvant chemo given alone.

Waitlist Available

FDA Approved Drug

Highlands Oncology Group (+1 Sites)Issam Makhoul, MD

Image of University of California, San Diego in La Jolla, United States.

Phase-Based Progress Estimates

Cirmtuzumab + Paclitaxelfor Breast Cancer

Waitlist Available

FDA Approved Drug

This trial will study cirmtuzumab in combination with paclitaxel to see if the combination is safe and has fewer side effects than paclitaxel alone. The study will also look at how well the combination works in treating patients with HER2 negative, metastatic breast cancer.

Waitlist Available

FDA Approved Drug

University of California, San DiegoBarbara Parker, MDOncternal Therapeutics, Inc

Image of Highlands Oncology Group in Fayetteville, United States.

Phase-Based Progress Estimates

Endocrine Therapyfor Breast Cancer

Waitlist Available

FDA Approved Drug

This trial looks at the safety of using abemaciclib in different combinations of drugs to treat breast cancer that has spread.

Waitlist Available

FDA Approved Drug

Highlands Oncology Group (+15 Sites)Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company

Image of Cross Cancer Institute in Edmonton, Canada.

Phase-Based Progress Estimates

Epirubicinfor Breast Cancer

FDA Approved Drug

This trial is testing whether using a person's genetic profile to calculate epirubicin dosage is more effective than the current method.

FDA Approved Drug

Cross Cancer InstituteMichael B Sawyer, MD FRCPC BScPharm

Image of Hospital of University of Pennsylvania in Philadelphia, United States.

Phase-Based Progress Estimates

Diagnostic Tomosynthesisfor Breast Cancer

Waitlist Available

This trial will compare the specificity of 2D mammography to a combination of 2D and 3D tomosynthesis imaging in breast cancer screening.

Waitlist Available

Hospital of University of Pennsylvania (+1 Sites)Emily F. Conant, MD

Image of Research Site in Detroit, United States.

Phase-Based Progress Estimates

AZD6244for Colon Neoplasms

Waitlist Available

FDA Approved Drug

This trial is testing a new drug in combination with standard chemotherapies to see if it is safe and effective for treating advanced solid tumors.

Waitlist Available

FDA Approved Drug

Research Site (+3 Sites)Patricia LoRusso, DOAstraZeneca

25 Breast Cancer Clinical Trials Near Me

Top Hospitals for Breast Cancer Clinical Trials

Image of Memorial Sloan Kettering Cancer Center in New York.

Memorial Sloan Kettering Cancer Center

New York

25Active Trials

204All Time Trials for Breast Cancer

1994First Breast Cancer Trial

Image of Dana-Farber Cancer Institute in Massachusetts.

Dana-Farber Cancer Institute

Boston

24Active Trials

206All Time Trials for Breast Cancer

1998First Breast Cancer Trial

Top Cities for Breast Cancer Clinical Trials

Image of Boston in Massachusetts.

Boston

94Active Trials

Dana-Farber Cancer InstituteTop Active Site

Image of Oakland in California.

Oakland

94Active Trials

Alta Bates Summit Medical Center - Summit CampusTop Active Site